Results 51 to 60 of about 2,458 (158)

In Silico Workflow for the Discovery of Natural Products Activating the G Protein-Coupled Bile Acid Receptor 1

Frontiers in Chemistry, 2018
The G protein-coupled bile acid receptor (GPBAR1) has been recognized as a promising new target for the treatment of diverse diseases, including obesity, type 2 diabetes, fatty liver disease and atherosclerosis.
Benjamin Kirchweger, Jadel M. Kratz, Angela Ladurner, Ulrike Grienke, Thierry Langer, Verena M. Dirsch, Judith M. Rollinger   +6 more
doaj   +1 more source

Radiotherapy‐Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments

MedComm, Volume 7, Issue 10, October 2026.
Radiotherapy for malignancies frequently injures the organs’ systems through oxidative stress, fibrosis, inflammation, and vascular damage. This review systematically maps the epidemiology, pathogenesis, and emerging therapies to propose a mechanism‑network‑targeted framework for integrated, personalized care in radiation oncology.
Xiaowen Ma, Xiaoxuan Zhang, Pujun Zhao, Jiaxin Yang, Zhihao Li, Xiaoyang Han, Yixuan Wang, Zhenzhen Cui, Nian Liu, Min Li   +9 more
wiley   +1 more source

The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Bile acids (BAs) serve not only as emulsifiers for lipid digestion but also as essential signaling molecules, governing various physiological and pathological processes through their interaction with the farnesoid X receptor (FXR) and the takeda G protein‐coupled receptor 5 (TGR5).
Jie Liu, Kui Sun, Hongmei Liu, Meiyang Zhu, Chunmeng Li, Yuqi He, Lin Qin   +6 more
wiley   +1 more source

BAR502 is dual FXR and GPBAR1 ligand.

, 2015
Data are mean ± SE of 3 experiments in duplicate* Activity of BAR502 toward GPBAR1 in a reporter assay was assessed in HEK293T cells transfected with a cAMP responsive element (CRE) cloned upstream to the luciferase gene (see Materials and Methods).
Barbara Renga (134135), Claudio D’Amore (770255), Angela Zampella (186821), Valentina Sepe (186788), Stefano Fiorucci (134151), Sabrina Cipriani (134132), Antonio Angelo De Tursi (770257), Maria Chiara Monti (186804), Michele Simonetti (770256), Adriana Carino (277117)   +9 more
core   +1 more source

Metabolic Syndrome: From Mechanisms to Therapeutic Interventions

MedComm, Volume 7, Issue 9, September 2026.
A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley   +1 more source

Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists

, 2019
In the recent years, bile acid receptors FXR and GPBAR1 have attracted the interest of scientific community and companies, as they proved promising targets for the treatment of several diseases, ranging from liver cholestatic disorders to metabolic ...
Carmen Festa, Simona De Marino, Valentina Sepe, Angela Zampella   +3 more
core   +1 more source

Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma

Advanced Science, Volume 13, Issue 44, 7 August 2026.
This review explains how chronic liver injury progresses toward hepatocellular carcinoma through interconnected changes in gut microbes, metabolism, immunity, fibrosis, and diet. It highlights microbial metabolites, bile‐acid signaling, immune dysfunction, and nutritional or microbiome‐based interventions as opportunities to identify risk earlier ...
Yi Hu, Caiyan Lin, Lijie Zhang, Xue Jiang, Huawen Li, Yangzhe Wu   +5 more
wiley   +1 more source

BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile

Frontiers in Chemistry
BAR502, a bile acid analogue, is active as dual FXR/GPBAR1 agonist and represents a promising lead for the treatment of cholestasis and NASH. In this paper we report the synthesis and the biological evaluation of a library of hybrid compounds prepared by
Claudia Finamore, Simona De Marino, Chiara Cassiano, Giuliano Napolitano, Pasquale Rapacciuolo, Silvia Marchianò, Michele Biagioli, Rosalinda Roselli, Cristina Di Giorgio, Carmen Festa, Stefano Fiorucci, Angela Zampella   +11 more
doaj   +1 more source

The gut microbiome organ

iMeta, Volume 5, Issue 4, August 2026.
The gut microbiome can be conceptualized as a distributed organ‐like functional system with spatially structured organization, broad biochemical capacity, and continuous bidirectional communication with the host. By transforming dietary, host‐derived, and environmental substrates into bioactive metabolites with endocrine‐like, immunomodulatory, and ...
Yang Bi, Weibin Song, Maria Glymenaki, Jie Hu, Xiru Li, Heng Huang, Yousong Peng, Shuaishuai Ni, Ornuma Haonon, Zhu Liu, Krai Daowtak, Xiaotao Shen, Huadong Peng, Jutarop Phetcharaburanin, Huiru Tang, Yulan Wang, Jia V. Li, Mizu Jiang, Nick Powell, Victor W. Zhong, Elaine Holmes, Yunlei Xianyu, Zhigang Liu   +22 more
wiley   +1 more source

GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells. [PDF]

PLoS ONE, 2014
GPBAR1/TGR5 is a novel plasma membrane-bound G protein-coupled bile acid (BA) receptor. BAs are known to induce the expression of inflammatory cytokines in the liver with unknown mechanism.
Guiyu Lou, Xiaoxiao Ma, Xianghui Fu, Zhipeng Meng, Wenyu Zhang, Yan-Dong Wang, Carl Van Ness, Donna Yu, Rongzhen Xu, Wendong Huang   +9 more
doaj   +1 more source